Endotoxin adsorbent based on immobilized human serum albumin

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 3, 1999, Pages 373-379

  Zimmermann, Michael ^a   Busch, Karin ^a   Kuhn, Stefan ^b   Zeppezauer, Michael ^b  

^a FRESENIUS AG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Endotoxin adsorption; Human serum albumin; Sepsis therapy

Indexed keywords

ACRYLIC ACID DERIVATIVE; CARBOXYL GROUP; CYTOKINE; ENDOTOXIN; ESCHERICHIA COLI ENDOTOXIN; HUMAN SERUM ALBUMIN; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; POLYMER; SALMONELLA ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADSORPTION; APHERESIS; BLOOD SAMPLING; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; HEMOPERFUSION; HUMAN; HUMAN CELL; LIMULUS LYSATE TEST; MEDICAL INSTRUMENTATION; MONOCYTE; NONHUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; SEPSIS;

ESCHERICHIA COLI; LIMULUS; LIMULUS AMOEBOCYTE; NEGIBACTERIA; SALMONELLA; SALMONELLA ABORTUS;

EID: 0032919912     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.062     Document Type: Conference Paper

References (34)

1. US Center for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990; 39:31-4.
2. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol 1978; 93:526-617.
3. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL-6 gene differently in response to LPS and IL-1. Cell Immunol 1989; 122:493-503.
4. Loppnow H, Libby P. Proliferating or IL-1 activated human vascular smooth muscle cells secrete copious IL-6. J Clin Invest 1990; 85:731-8.
5. Galanos C, Freudenberg MA, Katschinski T, Salomao R, Mossmann H, Kumazawa Y. Tumor necrosis factor and host response to endotoxin. In: Ryan JL, Morrison DC, editors. Immunopharmacology and pathophysiology. Boca Raton: CRC Press, 1992; 75-102.
6. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974; 140:797-811.
7. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76:2520-6.
8. Levi M, Tencate H, Vanderpoll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. J Am Med Assoc 1993; 270:975-9.
9. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79:319-23.
10. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
11. Guidet B, Barakett V, Vassal T, Petit JC, Offenstadt G. Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 1994; 106:1194-1201.
12. Hurley JC, Concordance of endotoxemia with gram-negative bacteremia in patients with gram-negative sepsis: a meta-analysis. J Clin Microbiol 1994; 32:2120-7.
13. McCartney AC, Banks JG, Clements GB, Sleigh JD, Tehrani M, Ledingham IM. Endotoxemia in septic shock: clinical and post-mortem correlations. Int Care Med 1983; 9:117-22.
14. Brandtzaeg PP, Keirulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159:195-204.
15. Parsons PE, Worthen GS, Moore EE, Tate RM, Henson PM. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 140:294-301.
16. Casey LC, Balk R A, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Int Med 1993; 119:771-8.
17. Wenzel R, Bone RC, Fein A, Quenzer R, Shentag J, Gorelick KJ, et al. Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in Gram-negative sepsis. Program and abstracts of the 31st Interscience Conference of Antimicrobial Agents and Chemotherapy 1991:294.
18. Ziegler EJ, Fischer CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324:429-36.
19. Luce JM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 1993; 21:1233-41.
20. Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350:1439-43.
21. Grootendorst AF. The potential role of hemofiltration in the treatment of patients with septic shock and multiple organ dysfunction syndrome. Adv Renal Displ Ther 1994; 1:176-84.
22. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23:288-96.
23. Nieter B, Sisova S, Klug C, Newie T, Manger T, Thieme M, et al. Plasmaaustausch bei septisch-toxischen Krankheitsbildern. Nieren- und Hochdruckkrankheiten 1991; 20:155-9.
24. Berlot G, Gullo A, Fasiolo S, Serra L, Silvestri L, Wörz M. Hemodynamic effects of plasma exchange in septic patients: preliminary report. Blood Purif 1997; 15:45-53.
25. Stegmayr BG. Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996; 14:94-101.
26. Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obset 1989; 168:323-31.
27. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167:412-17.
28. Kodama M, Hanasawa K, Tani T. Blood purification for critical care medicine: endotoxin adsorption. Therapeutic Apheresis 1997; 1:224-7.
29. Otto V, Schulze S, Zimmermann M. Vorrichtung zur Reinigung proteinhaltiger Lösungen, Verfahren zur Herstellung eines Trägermaterials für die Vorrichtung und Verwendung der Vorrichtung. European Patent EP 0 858 831. European Patent Office 1998.
30. Guideline on validation of the limulus amoebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration 1987.
31. Shimizu S, Tani Y, Yamada H, Tabata M, Murachi T. Enzymatic determination of serum-free fatty acids: a colorimetric method. Anal Biochem 1980; 107:193-8.
32. Skarnes R C, Rosen FS. Host dependent detoxification of bacterial endotoxins. In: Ajl SJ, Kadis S, Weinbaum G, editors. Microbial toxins. New York: Academic Press, 1971; 5:151-64.
33. Tesh, VL, Vukajlovich SW, Morrison DW. Endotoxin interactions with serum proteins: relationship to biological activity. In: Levin J, ten Cate JW, Büller HR, van Deventer SJH, Sturk A, editors. Bacterial endotoxins: pathophysiological effects, clinical significance, and pharmacological control. New York: Alan R. Liss, Inc., 1988:47-62.
34. Marra MN, Thornton MB, Snable JL, Wilde CG, Scott RW. Endotoxin-binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994; 22:559-65.